Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-63033-4
Abstract: The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal… read more here.
Keywords: subgroup; negative metastatic; asian patients; study ... See more keywords
Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Oncology"
DOI: 10.1155/2023/8740221
Abstract: Objective This study aims to evaluate the efficacy of bevacizumab combined with capecitabine in treating HER2-negative metastatic breast cancer through meta-analysis. Methods We searched literature from databases, including PubMed, Web of Science, Wiley Online Library,… read more here.
Keywords: her2 negative; bevacizumab combined; negative metastatic; group ... See more keywords
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-1287
Abstract: Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for… read more here.
Keywords: her2 negative; ribociclib palbociclib; receptor positive; negative metastatic ... See more keywords
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer"
DOI: 10.7150/jca.35109
Abstract: Triple negative breast cancer (TNBC) is characterized by distinctive biological features that confer an aggressive clinical behavior. In TNBC patients, the absence of well-defined driver pathways such as hormonal receptor expression or hyperactivation of the… read more here.
Keywords: negative metastatic; evidence; breast cancer; cancer ... See more keywords